Endonovo Therapeutics, Inc.
ENDV OTC
SEC CIK 1528172
Follow Endonovo Therapeutics
Weekly email: filings, results, news
Revenue, last year
$135.4K
+85.2% vs prior year
Net income
−$18.5M
−495% vs prior year
EPS, diluted
−$0.13
−160% vs prior year
Operating cash flow
−$678.8K
+31.2% vs prior year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY22 | $135.4K | −$18.5M |
| FY21 | $73.1K | −$3.1M |
| FY20 | $165.8K | −$395.6K |
| FY19 | $310.2K | −$17.3M |
| FY18 | $83.3K | −$6.4M |
| FY17 | - | −$10.8M |
| FY16 | - | −$5.3M |
| FY15 | $4.3K | −$6.8M |
| FY14 | $24.2K | −$959.5K |
| FY13 | $22.9K | −$2.9M |
| FY12 | $30.6K | −$1.9M |
| FY11 | $45.5K | −$94.1K |
| FY10 | $51.2K | −$69.4K |
| FY09 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY22 | 92.6% | −2411.7% | −13649.2% |
| FY21 | 79.5% | −3045.7% | −4247.2% |
| FY20 | 60.6% | −1756.5% | −238.6% |
| FY19 | 69.9% | −1228.1% | −5582.4% |
| FY18 | 84.5% | −4995.3% | −7729.5% |
| FY17 | - | - | - |
| FY16 | - | - | - |
| FY15 | 49.3% | −60132.7% | −158633.9% |
| FY14 | 36% | −9057.6% | −3966.2% |
| FY13 | 38.9% | −10607.6% | −12634.5% |
| FY12 | - | −5697.5% | −6260.6% |
| FY11 | - | −209.7% | −206.6% |
| FY10 | - | −152.3% | −135.5% |
| FY09 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | −$2.5M |
| FY18 | −$2.9M |
| FY17 | - |
| FY16 | - |
| FY15 | −$1M |
| FY14 | −$909.3K |
| FY13 | - |
| FY12 | - |
| FY11 | - |
| FY10 | - |
| FY09 | - |
- Endonovo Therapeutics
- Healthcare median
Show the numbers
| Year | Endonovo Therapeutics | Healthcare median |
|---|---|---|
| FY22 | −13649.2% | −128.5% |
| FY21 | −4247.2% | −129.2% |
| FY20 | −238.6% | −136.5% |
| FY19 | −5582.4% | −133.7% |
| FY18 | −7729.5% | −173.4% |
| FY17 | - | −176.7% |
| FY16 | - | −164.8% |
| FY15 | −158633.9% | −183.4% |
| FY14 | −3966.2% | −133% |
| FY13 | −12634.5% | −88.5% |
| FY12 | −6260.6% | −87.4% |
| FY11 | −206.6% | −76.3% |
| FY10 | −135.5% | - |
| FY09 | - | - |
News
No stories filed under Endonovo Therapeutics yet - coverage appears here as the news feed clusters it.